CEBP-altered B-ALL: Two transcriptomic profiles across the age spectrum

• by Jacqueline A. Rehn, Ashlee J. Thomson-Roberts, David T. Yeung, Deborah L. White, Elyse C. Page

• October 17, 2026

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

• October 15, 2026

• 1 min

Nipple or skin-sparing mastectomy flap: can preoperative breast-MRI predict post-operative complications?

• by L. I. Sgaramella, A. Pasculli, F. P. Prete, F. Cofone, M. Moschetta, M. Maruccia, R. Elia, M. Telegrafo, V. De Ruvo, M. Bisceglie, M. M. Miccoli, F. Palma, C. Testini, G. Giudice, M. Testini, A. Gurrado

• October 13, 2026

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

• by Meletios Athanasios Dimopoulos, Vania Hungria, Haitao Meng, Atanas Radinoff, Jian Li, Sosana Delimpasi, Ting Niu, Gabor Mikala, Tamas Masszi, Marcelo Capra, Michael Low, Angelo Maiolino, Yan Xu, Xavier Leleu, Vasiliki Pappa, Dominik Chraniuk, Tatiana Konstantinova, Iurii Osipov, Shawn Hakim, Chris Brawley, Gabriela Tubel, Astrid McKeown, Julia Boyle, Sumita Roy-Ghanta, Katja Weisel

• October 17, 2026